Desafio do diagnóstico da anemia hemolítica em pacientes infectados pela covid-19
Nenhuma Miniatura disponível
Data
2024-07
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Modalidade de acesso
Acesso fechado
Editora
Autores
SOUZA, Daiana Lisiane de
Orientador
ABREU, Fabiana Guichard de
Coorientador
Resumo
A Anemia Hemolítica Autoimune (AIHA) pode ser desencadeada pela infecção da Covid-19 em pacientes com ou sem diagnósticos prévios de outras doenças. O objetivo desta revisão integrativa foi a investigação da Anemia Hemolítica em relação a COVID-19 buscando não somente compreender as manifestações hematológicas durante ou pós a infecção, mas também identificar possíveis biomarcadores que auxiliem no diagnóstico precoce, monitoramento da progressão da doença, estratificação de riscos, implementação de protocolos de tratamentos mais eficazes contribuindo assim para a redução das complicações associadas a essa condição e, com esse conjunto de ações melhorar o prognóstico do paciente. Exames de imagens e laboratoriais específicos são imprescindíveis para o diagnóstico mais assertivo. É importante ressaltar que a anemia hemolítica desencadeada pela Covid-19 ainda está sendo estudada e necessita-se de mais discussões e pesquisas sobre o assunto para um diagnóstico precoce ao paciente, ter um tratamento mais eficaz e personalizado diminuindo assim a gravidade e as complicações causadas pela doença.
Autoimmune Hemolytic Anemia (AIHA) can be triggered by Covid-19 infection in patients with or without previous diagnoses of other diseases. The objective of this integrative review was to investigate Hemolytic Anemia in relation to COVID-19, seeking not only to understand the hematological manifestations during or after infection, but also to identify possible biomarkers that assist in early diagnosis, monitoring of disease progression, risk stratification , implementation of more effective treatment protocols, thus contributing to the reduction of complications associated with this condition and, with this set of actions, improving the patient's prognosis. Specific imaging and laboratory tests are essential for a more assertive diagnosis. It is important to highlight that hemolytic anemia triggered by Covid-19 is still being studied and more discussion and research is needed on the subject for an early diagnosis for the patient, having a more effective and personalized treatment, thus reducing the severity and complications caused. by the disease.
Autoimmune Hemolytic Anemia (AIHA) can be triggered by Covid-19 infection in patients with or without previous diagnoses of other diseases. The objective of this integrative review was to investigate Hemolytic Anemia in relation to COVID-19, seeking not only to understand the hematological manifestations during or after infection, but also to identify possible biomarkers that assist in early diagnosis, monitoring of disease progression, risk stratification , implementation of more effective treatment protocols, thus contributing to the reduction of complications associated with this condition and, with this set of actions, improving the patient's prognosis. Specific imaging and laboratory tests are essential for a more assertive diagnosis. It is important to highlight that hemolytic anemia triggered by Covid-19 is still being studied and more discussion and research is needed on the subject for an early diagnosis for the patient, having a more effective and personalized treatment, thus reducing the severity and complications caused. by the disease.
Palavras-chave
Anemia hemolítica, Covid-19, Biomarcadores, Diagnóstico precoce, Infecções